Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone

被引：0
|
作者：
Harousseau, J. L.
Nagler, A.
Sonneveld, P.
Blade, J.
Hajek, R.
Spencer, A.
Robak, T.
Xiu, L.
Zhuang, S. H.
Orlowski, R. Z.
机构：
[1] Hoteldieu Hosp, Nantes, France
[2] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[3] Erasmus MC, Rotterdam, Netherlands
[4] Hosp Clin I Prov, Barcelona, Spain
[5] Interni Hematoonkol Klin Fak Brno, Brno, Czech Republic
[6] Alfred Hosp, Melbourne, Vic, Australia
[7] Med Univ Lodz, Lodz, Poland
[8] Johnson & Johnson PRD, Raritan, NJ USA
[9] Univ N Carolina, Chapel Hill, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8002
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Erratum to: pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients
    Gabriele Buda
    Enrico Orciuolo
    Sara Galimberti
    Matteo Pelosini
    Mario Petrini
    Annals of Hematology, 2011, 90 (7) : 863 - 863
  • [42] Association of bortezomib, doxorubicin and dexamethasone (PAD) in relapsed and refractory multiple myeloma patients
    Palumbo, A.
    Gay, F.
    Falcone, A.
    Pescosta, N.
    Callea, V
    Caravita, T.
    Morabito, F.
    Falco, P.
    Larocca, A.
    Avonto, I
    Musto, P.
    Cascavilla, N.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 31 - 32
  • [43] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Padmanabhan, Swaminathan
    Yu, Jihnhee
    Ailawadhi, Sikander
    Sher, Taimur
    Mohr, Alice
    Bernstein, Zale P.
    Barcos, Maurice
    Patel, Mehul
    Iancu, Dan
    Lee, Kelvin
    Czuczman, Myron S.
    LEUKEMIA & LYMPHOMA, 2009, 50 (07) : 1096 - 1101
  • [44] Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Osman, Keren
    Richards, Kristy L.
    Ferraro, Madlyn
    Garcia, Reynaldo
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic
    Strader, John
    Orlowski, Robert Z.
    Hurd, David Duane
    BLOOD, 2011, 118 (21) : 1705 - 1706
  • [45] BORTEZOMIB, PEGYLATED LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE (B-PEGHLD-D) AS THERAPY FOR PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOIVIA
    Gozzetti, A.
    Marchini, E.
    Fabbri, A.
    Bocchia, M.
    Defina, M.
    Lauria, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 437 - 437
  • [46] Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
    Sonneveld, P.
    Hajek, R.
    Nagler, A.
    Spencer, A.
    Blade, J.
    Robak, T.
    Zhuang, S. H.
    Harousseau, J. L.
    Fruchtman, S.
    Orlowski, R. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] EFFICACY OF THE COMBINATION THERAPY OF LIPOSOMAL ADRYAMICIN, BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ABCD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Romano, A.
    Chiarenza, A.
    Gorgone, A.
    Schinocca, L.
    Uccello, G.
    Cavalli, M.
    Fiumara, P.
    Motta, G.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA, 2012, 97 : 607 - 607
  • [48] Bortezomib in combination with bendamustine and preduisone in the treatment of patients with refractory/relapsed multiple myeloma
    Poenisch, Wolfram
    Bourgeois, Malvina
    Wang, Song-Yau
    Heyn, Simone F.
    Jaekel, Nadja
    Braunert, Leanthe
    Rohrberg, Robert
    Hurtz, Hans Juergen
    Hoffmann, Franz Albert
    Schwarzer, Andreas
    Becker, Cornelia
    Al Ali, Haifa
    Niederwieser, Dietger W.
    BLOOD, 2007, 110 (11) : 799A - 800A
  • [49] Bendamustine and prednisone in combination with Bortezomib in the treatment of patients with relapsed/refractory multiple myeloma
    Poenisch, W.
    Bourgeois, M.
    Heyn, S.
    Wagner, I
    Jaekel, N.
    Rohrberg, R.
    Hurtz, H. -J.
    Schmalfeld, M.
    Assmann, M.
    Edelmann, T.
    Mohren, M.
    Hoffmann, F. A.
    Schwarzer, A.
    Hensel, G.
    Loeschke, K.
    Becker, C.
    Krahl, R.
    Al-Ali, H. K.
    Niederwieser, D.
    ONKOLOGIE, 2012, 35 : 144 - 144
  • [50] Bortezomib plus doxorubicin combination slows progression of multiple myeloma
    不详
    CANCER BIOLOGY & THERAPY, 2007, 6 (01) : 9 - 10
12345